The USPSTF and randomized screening trials provide the primary evidence supporting one-time ultrasonography screening in men aged 65 to 75 who have ever smoked, showing reduced AAA-related mortality when screening is coupled with appropriate surveillance and treatment.
The USPSTF found a moderate net benefit for that group, recommended selective offering for never-smokers, and recommended against routine screening in women because of low prevalence of clinically important AAAs and a poor balance of benefits versus harms.
Surveillance recommendations for screen-detected AAAs follow established diameter thresholds: small AAAs (3.0–3.9 cm) are monitored with periodic ultrasound, intermediate AAAs (4.0–5.4 cm) are followed more closely, and repair is generally considered at the 5.5 cm threshold; example surveillance intervals cited include repeat ultrasound every 6 months for AAAs >4 cm and every 2 years for smaller AAAs.
For post-EVAR surveillance and endoleak detection, pooled data show that color duplex ultrasound (unenhanced and enhanced) has lower sensitivity than CT angiography for endoleak detection (pooled sensitivity for unenhanced duplex ~66%, enhanced ~81%; specificity high for unenhanced ~93%).
Recent and emerging literature explores expanded screening criteria beyond USPSTF recommendations and multiple potential applications of AI for opportunistic detection, segmentation, and prediction; preliminary AI studies report high diagnostic metrics but are limited by single-center designs, sampling bias, limited external validation, and performance limits for small aneurysms.
Because of these limitations, AI applications for screening, operative planning, growth/rupture prediction, and outcome prediction are considered experimental pending further validation.